Skip to content
Lofexidine
Lucemyra (lofexidine) is a small molecule pharmaceutical. Lofexidine was first approved as Lucemyra on 2018-05-16. It is used to treat substance withdrawal syndrome in the USA. It is known to target alpha-2B adrenergic receptor, alpha-2A adrenergic receptor, and alpha-2C adrenergic receptor.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
chemically-induced disordersD064419
mental disordersD001523
Trade Name
FDA
EMA
Lucemyra
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Lofexidine hydrochloride
Tradename
Company
Number
Date
Products
LUCEMYRAUS WorldMedsN-209229 RX2018-05-16
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
lucemyraNew Drug Application2022-03-01
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
substance withdrawal syndromeEFO_0005800D013375
Agency Specific
FDA
EMA
Expiration
Code
LOFEXIDINE HYDROCHLORIDE, LUCEMYRA, USWM
2023-05-16NCE
Patent Expiration
No data
ATC Codes
N: Nervous system drugs
N07: Other nervous system drugs in atc
N07B: Drugs used in addictive disorders
N07BC: Drugs used in opioid dependence
N07BC04: Lofexidine
HCPCS
No data
Clinical
Clinical Trials
203 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Bipolar disorderD001714EFO_0000289F30.93521331775
Major depressive disorderD003865EFO_0003761F223337418
DepressionD003863F33.91239216
Depressive disorderD003866EFO_1002014F32.A11326
Treatment-resistant depressive disorderD06121811316
ManiaD000087122F303216
Cognitive dysfunctionD060825G31.841214
SchizophreniaD012559EFO_0000692F20213
Psychotic disordersD011618F20.81123
DementiaD003704F03112
Show 5 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Amyotrophic lateral sclerosisD000690EFO_0000253G12.21313
Attempted suicideD013406EFO_0004321T14.91222
SuicideD0134051112
Psychophysiologic disordersD011602F45.911
Anxiety disordersD001008EFO_0006788F41.111
Autism spectrum disorderD000067877F84.011
AlcoholismD000437EFO_0003829F10.111
StrokeD020521EFO_0000712I63.911
Machado-joseph diseaseD017827EFO_0004135111
Conduct disorderD019955EFO_0004216F9111
Show 5 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Spinal cord injuriesD013119EFO_1001919456
Alzheimer diseaseD000544EFO_0000249F0333
Covid-19D000086382U07.1112
Small cell lung carcinomaD0557521112
Spinocerebellar ataxiasD020754112
Brain neoplasmsD001932EFO_0003833C7111
Progressive supranuclear palsyD013494EFO_0002512G23.1111
Thyroid neoplasmsD013964EFO_000384111
Borderline personality disorderD001883HP_0012076F60.311
Dysthymic disorderD019263EFO_0008623F34.111
Show 16 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Myeloid leukemia acuteD015470C92.0112
Colorectal neoplasmsD01517911
Stomach neoplasmsD013274EFO_0003897C1611
Esophageal neoplasmsD004938C1511
Megakaryoblastic leukemia acuteD007947C94.211
Monocytic leukemia acuteD00794811
Myelomonocytic leukemia acuteD015479C92.511
Erythroblastic leukemia acuteD004915EFO_1001257C94.011
Parkinson diseaseD010300EFO_0002508G2011
Type c niemann-pick diseaseD052556Orphanet_646E75.24211
Show 4 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Nonvital toothD01955333
Prosthesis failureD01147522
Tooth wearD05708522
Healthy volunteers/patients11
Dental cariesD003731EFO_0003819K0211
VitiligoD014820EFO_0004208L8011
Tooth discolorationD014075K03.611
Tooth lossD01638811
Dental implantsD01592111
Sleep bruxismD020186G47.6311
Show 31 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameLOFEXIDINE
INNlofexidine
Description
Lofexidine is a member of imidazoles, a dichlorobenzene, an aromatic ether and a carboxamidine. It has a role as an alpha-adrenergic agonist and an antihypertensive agent.
Classification
Small molecule
Drug class
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC(Oc1c(Cl)cccc1Cl)C1=NCCN1
Identifiers
PDB
CAS-ID31036-80-3
RxCUI28863
ChEMBL IDCHEMBL17860
ChEBI ID51368
PubChem CID30668
DrugBankDB04948
UNII IDUI82K0T627 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
ADRA2B
ADRA2B
ADRA2A
ADRA2A
ADRA2C
ADRA2C
Organism
Homo sapiens
Gene name
ADRA2B
Gene synonyms
ADRA2L1, ADRA2RL1
NCBI Gene ID
Protein name
alpha-2B adrenergic receptor
Protein synonyms
ADRA2B adrenergic, alpha-2B-, receptor, Alpha-2 adrenergic receptor subtype C2, alpha-2-adrenergic receptor-like 1, Alpha-2B adrenoceptor, Alpha-2B adrenoreceptor, Alpha-2BAR, G-protein coupled receptor
Uniprot ID
Mouse ortholog
Adra2b (11552)
alpha-2B adrenergic receptor (P30545)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 608 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
16,902 adverse events reported
View more details